Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for BRTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
March 31, 2026 -3.808M
December 31, 2025 -2.415M
September 30, 2025 -2.901M
June 30, 2025 -2.694M
March 31, 2025 -2.779M
December 31, 2024 -2.348M
September 30, 2024 -1.700M
June 30, 2024 -1.865M
March 31, 2024 -2.318M
December 31, 2023 -1.588M
September 30, 2023 -1.179M
June 30, 2023 -1.284M
March 31, 2023 -2.379M
December 31, 2022 -1.573M
September 30, 2022 -1.452M
June 30, 2022 -1.251M
March 31, 2022 -1.595M
December 31, 2021 -1.145M
September 30, 2021 -0.6294M
June 30, 2021 -0.7418M
March 31, 2021 -0.8137M
December 31, 2020 -0.5721M
September 30, 2020 -0.5231M
June 30, 2020 -0.4204M
March 31, 2020 -0.4486M
Date Value
December 31, 2019 -1.811M
September 30, 2019 -1.711M
June 30, 2019 -1.417M
March 31, 2019 -1.980M
December 31, 2018 -1.553M
September 30, 2018 -1.353M
June 30, 2018 -1.040M
March 31, 2018 -1.158M
December 31, 2017 -1.360M
September 30, 2017 -0.5092M
June 30, 2017 -0.766M
March 31, 2017 -1.219M
December 31, 2016 -1.062M
September 30, 2016 -1.206M
June 30, 2016 -1.018M
March 31, 2016 -1.718M
December 31, 2015 -1.054M
September 30, 2015 -0.5836M
June 30, 2015 -0.8096M
March 31, 2015 -0.6748M
December 31, 2014 -0.6343M
September 30, 2014 -0.8337M
June 30, 2014 -0.9532M
March 31, 2014 -0.8067M
December 31, 2013 -0.7638M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Myriad Genetics, Inc. -8.30M
CareDx, Inc. 30.60M
Natera, Inc. 54.79M
Exagen, Inc. 3.988M
Sera Prognostics, Inc. -6.311M